# Integer Holdings Corp: Form 10-Q for the period ended Sep 27, 2019

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2019-10-31
- Accepted by EDGAR: Oct 31, 2019, 16:00 ET
- Period: 2019-09-27
- Accession: 0001114483-19-000025
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448319000025/form10-q2019x09x27.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448319000025/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-27.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-06-29 to 2019-09-27 | $303.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-12-29 to 2019-09-27 | $932.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-06-29 to 2019-09-27 | $210.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-12-29 to 2019-09-27 | $653.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-06-29 to 2019-09-27 | $93.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-12-29 to 2019-09-27 | $279.0m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2019-06-29 to 2019-09-27 | $32.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2018-12-29 to 2019-09-27 | $101.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-06-29 to 2019-09-27 | $46.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-12-29 to 2019-09-27 | $135.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-06-29 to 2019-09-27 | $12.3m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-12-29 to 2019-09-27 | $39.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-06-29 to 2019-09-27 | $4.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-12-29 to 2019-09-27 | $15.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-06-29 to 2019-09-27 | $30.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-12-29 to 2019-09-27 | $85.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-06-29 to 2019-09-27 | $0.92 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-12-29 to 2019-09-27 | $2.58 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-06-29 to 2019-09-27 | $0.94 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-12-29 to 2019-09-27 | $2.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-06-29 to 2019-09-27 | 33,068,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-12-29 to 2019-09-27 | 33,019,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-12-29 to 2019-09-27 | $112.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-12-29 to 2019-09-27 | $24.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-09-27 | $14.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-27 | $453.1m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-27 | $2.36bn | us-gaap:Assets |
| Current liabilities | at 2019-09-27 | $188.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-27 | $1.23bn | us-gaap:Liabilities |
| Long-term debt | at 2019-09-27 | $790.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-27 | $37.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2019-09-27 | $1.13bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 61,910 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the fiscal year ended December 28, 2018. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- future sales, expenses, and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- our ability to identify trends within our industries and to offer products and services that meet the changing needs of those markets;
- our ability to remain in compliance with the financial covenants contained in the agreement governing our Senior Secured Credit Facilities; and
- projected capital expenditures.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: our indebtedness, our inability to pay principal and interest on this outstanding indebtedness or to remain in compliance with financial and other covenants under our Senior Secured Credit Facilities, and the risk that this indebtedness limits our ability to invest in our business and overall financial flexibility; our dependence upon a limited number of customers; customer ordering patterns; product obsolescence; our inability to market current or future products; pricing pressure from customers; our ability to timely and successfully implement cost savings and consolidation initiatives; our reliance on third-party suppliers for raw materials, products and subcomponents; fluctuating operating results; our inability to maintain high-quality standards for our products; challenges to our intellectual property rights; product liability claims; product field actions or recalls; our inability to successfully consummate and integrate acquisitions and to realize synergies and to operate these acquired businesses in accordance with expectations; our unsuccessful expansion into new markets; our failure to develop new products; the timing, progress and ultimate success of pending regulatory actions and approvals; our inability to obtain licenses to key technology; regulatory changes, including health care reform, or consolidation in the healthcare industry; global economic factors, including currency exchange rates and interest rates; the resolution of various legal actions brought against the Company; ongoing impacts resulting from the U.S. Tax Cuts and Jobs Act (the “Tax Reform Act”), including the Global Intangible Low-Taxed Income (“GILTI”) tax; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission. Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

- 31 -

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Advanced Surgical, Orthopedics & Portable Medical, Cardio & Vascular and Cardiac & Neuromodulation product lines and the Non-Medical segment is comprised of the Electrochem product line.

Historically, we have utilized a 52/53-week fiscal year ending on the Friday nearest December 31. On October 9, 2019, Integer’s Board of Directors approved a change in our fiscal year from a year ending on the Friday nearest December 31 to a year ending on December 31 each year. Upon receipt of the customary approval of the lenders under our Senior Secured Credit Facilities, our current fiscal year will end on December 31, 2019, instead of January 3, 2020, with subsequent fiscal years beginning on January 1 and ending on December 31 of each year. The change in fiscal year was implemented so that, on a going forward basis, each of our fiscal years (except for leap years) has 365 days, which will allow for consistent comparison between fiscal years. Our first three fiscal quarters in each fiscal year will continue to end on the Friday nearest March 31, June 30 and September 30, respectively. Fiscal year 2018 ended on December 28, 2018 and was a fifty-two week period.

The third quarter of 2019 and 2018 each contained 13 weeks and ended on September 27 and September 28, respectively, and were not impacted by the change in fiscal year.

### Discontinued Operations and Divestiture

On July 2, 2018, we completed the sale of the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) for net cash proceeds of approximately $581 million, resulting in the recognition of a pre-tax gain of approximately $195 million during the year ended December 28, 2018. In connection with the sale, the parties executed a transition services agreement whereby we provided certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. Viant paid us for these services as specified in the transition services agreement, which were complete as of June 28, 2019. In addition, the parties executed long-term supply agreements under which the parties have agreed to supply the other with certain products at prices specified in the agreements for a term of three years.

On June 14, 2019, Viant paid us $4.8 million for the final net working capital adjustment, which was recognized as gain on sale from discontinued operations, net of taxes, during the quarter ended June 28, 2019.

The results of operations of the AS&O Product Line have been classified as discontinued operations for all periods presented. Prior period amounts have been reclassified to conform to the continuing operations reporting presentation. All results and information presented exclude the AS&O Product Line unless otherwise noted.

Refer to Note 2 “Discontinued Operations, Divestitures and Acquisitions” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the divestiture of the AS&O Product Line.

### Recent Acquisitions

In October 2019, we purchased certain assets of US BioDesign, LLC, a developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition adds a differentiated capability related to the development and manufacture of complex braided and formed biomedical structures to our broad portfolio, that we believe further positions us as a partner of choice for innovative medical technologies.

### Strategic Overview

We continue to take steps to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products. In addition to our portfolio strategy, we have launched the execution of six key operational strategic imperatives designed to drive excellence in everything we do:

- Sales Force Excellence: We are changing the organization structure to match product line growth strategies and customer needs. This change is about getting more out of the capabilities we already have, and will increase individual accountability and clarity of ownership.
- Market Focused Innovation: We are ensuring we get the most return on our research and development investments. Integer is currently focusing on getting a clearer picture of how we spend our money and ensuring we are spending it in the right places so we can increase investments to drive future growth.
- 32 -
- Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.
- Business Process Excellence: Integer is taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.
- Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.
- Leadership Capability: We have a robust plan to make leadership a competitive advantage for Integer, and since the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

### Revised 2019 Outlook(a)

(dollars in millions, except per share amounts)

|  | GAAP |  | Non-GAAP(b) |  |
| --- | --- | --- | --- | --- |
| **Continuing Operations:** | **As Reported** | **Growth** | **Adjusted** | **Growth** |
| Sales | $1,265 to $1,280 | 4% to 5% | $1,265 to $1,280 | 4% to 6% |
| Income | $106 to $110 | 125% to 134% | $150 to $154 | 21% to 23% |
| EBITDA | N/A | N/A | $282 to $286 | 9% to 10% |
| Earnings per Diluted Share | $3.22 to $3.32 | 123% to 130% | $4.55 to $4.65 | 20% to 22% |

(a) Except as described below, further reconciliations by line item to the closest corresponding financial measure prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for Adjusted Sales, Adjusted Income, earnings before interest, taxes, depreciation, and amortization (“EBITDA”), and Adjusted EBITDA and Adjusted Earnings per diluted share (“EPS”), all from continuing operations, included in our “2019 Outlook” above, are not available without unreasonable efforts on a forward-looking basis due to the high variability, complexity and visibility of the charges excluded from these non-GAAP financial measures.

(b) Adjusted income and diluted EPS, both from continuing operations, for 2019 are expected to consist of GAAP income from continuing operations and diluted EPS from continuing operations, excluding items such as intangible amortization, certain legal expenses, reorganization and realignment costs, asset dispositions, severance, gains and losses on equity investments and loss and loss on extinguishment of debt totaling approximately $56 million, pre-tax. The after-tax impact of these items is estimated to be approximately $44 million, or approximately $1.33 per diluted share.

Adjusted EBITDA from continuing operations is expected to consist of Adjusted income from continuing operations, excluding items such as depreciation, interest, stock-based compensation and taxes, which are expected to be approximately $132 million.

- 33 -

### Financial Overview of Continuing Operations

Income from continuing operations for the third quarter of 2019 was $30.6 million, or $0.92 per diluted share, compared to a loss from continuing operations of $8.3 million, or $0.26 per diluted share, for the third quarter of 2018. Income from continuing operations for the first nine months of 2019 was $80.2 million, or $2.43 per diluted share per diluted share, compared to income from continuing operations of $27.8 million, or $0.86 per diluted share, for the first nine months of 2018. These year over year variances are primarily the result of the following:

- Sales from continuing operations for the third quarter of 2019 decreased $1.5 million and increased $20.5 million for the first nine months of 2019 when compared to the same periods in 2018. The increase for the first nine months of 2019 was due to growth in Cardio & Vascular, Cardiac & Neuromodulation and Electrochem sales, partially offset by lower Advanced Surgical, Orthopedic & Portable Medical sales in comparison to the first nine months of 2018. During the third quarter and first nine months of 2019, price reductions given to our larger OEM customers in return for long-term volume commitments lowered sales by $3.2 million and $9.6 million, respectively, in comparison to the same periods in 2018. In comparison to the prior year periods, foreign currency exchange rates decreased sales from continuing operations by approximately $0.6 million and $2.2 million for the third quarter and first nine months of 2019, respectively.
- Gross profit from continuing operations for the third quarter of 2019 increased $1.5 million, compared to the same period in 2018, primarily due to a $3.0 million decrease in cost of sales, partially offset by a decrease in sales and price reductions given to our customers. Gross profit from continuing operations for the first nine months of 2019 increased $4.8 million, compared to the same period in 2018, primarily due to the increase in sales from continuing operations and benefits of production efficiencies achieved, partially offset by price reductions given to our customers and inflation.
- Operating expenses for the third quarter and first nine months of 2019 were lower by $3.6 million and $14.4 million, respectively, compared to the same periods in 2018, due to decreases in all categories of operating expenses.
- Interest expense for the third quarter and first nine months of 2019 decreased by $42.2 million and $45.6 million, respectively, compared to the same periods in 2018, primarily due to lower outstanding debt balances due to the repayment of debt over the last year and extinguishment of debt charges included in the 2018 periods related to the repayment of indebtedness in connection with the divestiture of the AS&O Product Line. Debt extinguishment expenses included in interest expense for the third quarter and first nine months of 2019 were lower by $40.4 million and $40.9 million, respectively, compared to the same periods in 2018.
- During the third quarter and first nine months of 2019, we recognized a net gain on equity investments of $1.0 million and a net loss of $0.7 million, respectively, and net gains for the third quarter and first nine months of 2018 of $0.3 million and $5.5 million, respectively. Gains and losses on equity investments are generally unpredictable in nature.
- Other income, net for the third quarter and first nine months of 2019 was $0.4 million and $0.9 million, respectively, compared to other loss of $1.7 million and $0.3 million during the same periods in 2018, primarily due to foreign currency gains in the 2019 periods compared to foreign currency losses for the same periods in 2018.
- We recorded an income tax provision of $4.9 million for the third quarter of 2019, compared to a benefit of $6.2 million for the third quarter of 2018. The income tax provision for the first nine months of 2019 and 2018 was $15.3 million and $8.0 million, respectively. Refer to Note 9 “Income Taxes” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report and the “Provision for Income Taxes” section of this Item for additional information.

### Our CEO’s View

We delivered strong income growth in the third quarter, on flat sales. We continue to execute on our operational strategy and have increased our full year profit outlook. In the fourth quarter of 2019, we executed a bolt-on acquisition to add complex braiding for high-growth C&V markets. Strong cash flow generation enabled continued reductions to our debt leverage ratio.

- 34 -

### Our Financial Results of Continuing Operations

The following tables present selected financial information from continuing operations derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share). All financial information presented is from continuing operations unless otherwise specified.

| Medical Sales: | Three Months Ended September 27, 2019 | September 28, 2018 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $148,581 | $150,230 | $(1,649) | (1.1)% |
| Cardiac & Neuromodulation | 106,533 | 109,620 | (3,087) | (2.8)% |
| Advanced Surgical, Orthopedics & Portable Medical | 34,310 | 32,789 | 1,521 | 4.6% |
| Total Medical Sales | 289,424 | 292,639 | (3,215) | (1.1)% |
| **Non-Medical** | 14,163 | 12,449 | 1,714 | 13.8% |
| Total Sales | 303,587 | 305,088 | (1,501) | (0.5)% |
| Cost of sales | 210,201 | 213,165 | (2,964) | (1.4)% |
| Gross profit | 93,386 | 91,923 | 1,463 | 1.6% |
| Gross profit as a % of sales | 30.8% | 30.1% |  |  |
| Selling, general and administrative expenses (“SG&A”) | 32,935 | 34,091 | (1,156) | (3.4)% |
| SG&A as a % of sales | 10.8% | 11.2% |  |  |
| Research, development and engineering costs (“RD&E”) | 11,729 | 12,234 | (505) | (4.1)% |
| RD&E as a % of sales | 3.9% | 4.0% |  |  |
| Other operating expenses | 2,241 | 4,139 | (1,898) | (45.9)% |
| Operating income | 46,481 | 41,459 | 5,022 | 12.1% |
| Operating margin | 15.3% | 13.6% |  |  |
| Interest expense | 12,337 | 54,526 | (42,189) | (77.4)% |
| Gain on equity investments, net | (986) | (291) | (695) | NM |
| Other (income) loss, net | (369) | 1,684 | (2,053) | NM |
| Income (loss) from continuing operations before taxes | 35,499 | (14,460) | 49,959 | NM |
| Provision for (benefit from) income taxes | 4,913 | (6,157) | 11,070 | NM |
| Effective tax rate | 13.8% | 42.6% |  |  |
| Income (loss) from continuing operations | $30,586 | $(8,303) | $38,889 | NM |
| Income (loss) from continuing operations as a % of sales | 10.1% | (2.7)% |  |  |
| Diluted earnings (loss) per share from continuing operations | $0.92 | $(0.26) | $1.18 | NM |

- 35 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

| Medical Sales: | Nine Months Ended September 27, 2019 | September 28, 2018 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $451,552 | $435,859 | $15,693 | 3.6% |
| Cardiac & Neuromodulation | 337,932 | 334,471 | 3,461 | 1.0% |
| Advanced Surgical, Orthopedics & Portable Medical | 98,544 | 101,481 | (2,937) | (2.9)% |
| Total Medical Sales | 888,028 | 871,811 | 16,217 | 1.9% |
| **Non-Medical** | 44,429 | 40,167 | 4,262 | 10.6% |
| Total Sales | 932,457 | 911,978 | 20,479 | 2.2% |
| Cost of sales | 653,477 | 637,758 | 15,719 | 2.5% |
| Gross profit | 278,980 | 274,220 | 4,760 | 1.7% |
| Gross profit as a % of sales | 29.9% | 30.1% |  |  |
| SG&A | 101,034 | 107,300 | (6,266) | (5.8)% |
| SG&A as a % of sales | 10.8% | 11.8% |  |  |
| RD&E | 34,720 | 38,445 | (3,725) | (9.7)% |
| RD&E, Net as a % of sales | 3.7% | 4.2% |  |  |
| Other operating expenses | 8,239 | 12,615 | (4,376) | (34.7)% |
| Operating income | 134,987 | 115,860 | 19,127 | 16.5% |
| Operating margin | 14.5% | 12.7% |  |  |
| Interest expense | 39,779 | 85,355 | (45,576) | (53.4)% |
| (Gain) loss on equity investments, net | 666 | (5,545) | 6,211 | NM |
| Other (income) loss, net | (921) | 257 | (1,178) | NM |
| Income from continuing operations before taxes | 95,463 | 35,793 | 59,670 | NM |
| Provision for income taxes | 15,289 | 7,956 | 7,333 | 92.2% |
| Effective tax rate | 16.0% | 22.2% |  |  |
| Income from continuing operations | $80,174 | $27,837 | $52,337 | NM |
| Income from continuing operations as a % of sales | 8.6% | 3.1% |  |  |
| Diluted earnings per share from continuing operations | $2.43 | $0.86 | $1.57 | NM |

NM Calculated amount not meaningful

- 36 -

### Product Line Sales from Continuing Operations

For the third quarter and first nine months of 2019, Cardio & Vascular sales decreased $1.6 million, or 1%, and increased $15.7 million or 4%, respectively, versus the comparable 2018 periods. The decrease in the third quarter of 2019 compared to the same quarter in 2018 was primarily due to an end of life electrophysiology program, which experienced the largest quarterly decline to date, partially offset by peripheral vascular and structural heart growth. The increase in the first nine months of 2019 was driven by customer share gains, new product launches, and the impact of a long-term agreement with a current customer related to their existing products. During the third quarter and first nine months of 2019, price reductions lowered Cardio & Vascular sales by $1.4 million and $4.9 million, respectively, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations decreased Cardio & Vascular sales for the third quarter and first nine months of 2019 by $0.7 million and $1.6 million, respectively, in comparison to the 2018 periods primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2019, Cardiac & Neuromodulation sales decreased $3.1 million, or 3%, and increased $3.5 million or 1%, respectively, versus the comparable 2018 periods. The decrease in the third quarter of 2019 compared to the same quarter in 2018 was primarily due to neuromodulation customer demand shift to the fourth quarter and flat cardiac rhythm management sales. The increase in the first nine months of 2019 in Cardiac & Neuromodulation sales was mainly due to the impact of the aforementioned long-term customer agreement. During the third quarter and first nine months of 2019, price reductions lowered Cardiac & Neuromodulation sales by $1.7 million and $5.0 million, respectively, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our AS&O Product Line, Viant, under the long-term supply agreements (“LSAs”) entered into as of the closing of the divestiture for the sale of products by the Company to Viant. For the third quarter and first nine months of 2019, Advanced Surgical, Orthopedic & Portable Medical sales increased $1.5 million, or 5%, and decreased $2.9 million or 3%, respectively, versus the comparable 2018 periods. The quarterly sales increase was driven by an increase in the advanced surgical base products and new product launches in Portable Medical, which was more than offset on a year-to-date basis by a decline in advanced surgical and orthopedic products. Price reductions lowered Advanced Surgical, Orthopedic & Portable Medical sales for the third quarter and first nine months of 2019 by $0.2 million, in comparison to the 2018 periods. Foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

For the third quarter and first nine months of 2019, Non-Medical sales increased $1.7 million, or 14%, and $4.3 million or 11%, respectively, versus the comparable 2018 periods. The increases in Non-Medical sales were primarily due to energy market demand and favorable military order timing. Price and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the third quarter and first nine months of 2019 in comparison to the same periods of 2018.

- 37 -

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Price(a) | (1.1)% | (1.0)% |
| Mix(b) | (0.1) | 0.1 |
| Incentive compensation(c) | 0.1 | (0.1) |
| Production efficiencies and volume leverage(d) | 1.8 | 0.8 |
| Total percentage point change to gross profit as a percentage of sales | 0.7% | (0.2)% |

(a) Our Gross Margin for the third quarter and first nine months of 2019 has been negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.

(b) Amounts represent the impact to our Gross Margin attributable to favorable (unfavorable) changes in the mix of product sales during the period.

(c) Amounts represent the impact to our Gross Margin attributable to our cash and stock incentive compensation programs, including performance-based compensation, which is accrued based upon actual results achieved.

(d) Represents various increases and decreases to our Gross Margin. Overall, our Gross Margin for the third quarter and first nine months of 2019 was positively impacted by production efficiencies, mainly due to our Manufacturing Excellence initiative, as well as lower amortization expense and, on a year-to-date basis, higher sales volume.

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Transition services agreement(a) | $1,834 | $(924) |
| Professional fees(b) | (1,267) | (1,094) |
| Compensation and benefit costs | (748) | (1,472) |
| Depreciation and amortization | (86) | (740) |
| Other general and administrative expenses | (889) | (2,036) |
| Net decrease in SG&A Expenses | $(1,156) | $(6,266) |

(a) Represents the amount included in SG&A Expenses, which was charged to Viant for transition services provided beginning in the third quarter of 2018 through the second quarter of 2019. We executed a transition services agreement in conjunction with the sale of the AS&O Product Line, whereby we agreed to provide certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. This provision of services under the agreement was completed during the second quarter of 2019.

(b) Professional fees decreased during the third quarter and first nine months of 2019 compared to the prior year period, primarily due to lower legal costs, including legal expenses incurred related to our on-going patent infringement case. Refer to Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for information related to this patent infringement litigation.

### RD&E

RD&E costs for the three and nine months ended September 27, 2019 was $11.7 million and $34.7 million, respectively, compared to $12.2 million and $38.4 million for the three and nine months ended September 28, 2018. RD&E costs are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

- 38 -

### Other Operating Expenses

Refer to Note 8 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses (“OOE”) is comprised of the following (in thousands):

|  | Three Months Ended September 27, 2019 | September 28, 2018 | Nine Months Ended September 27, 2019 | September 28, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Strategic reorganization and alignment(a) | $962 | $2,643 | $4,352 | $8,424 |
| Manufacturing alignment to support growth(b) | 515 | 877 | 1,661 | 2,493 |
| Consolidation and optimization expenses(c) | — | 137 | — | 698 |
| Asset dispositions, severance and other(d) | 764 | 482 | 2,226 | 1,000 |
| Total other operating expenses | $2,241 | $4,139 | $8,239 | $12,615 |

(a) As a result of the strategic review of our customers, competitors and markets, we began taking steps in the fourth quarter of 2017 to better align our resources in order to enhance the profitability of our portfolio of products. These initiatives include improving our business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and our future strategic direction. Expenses for the third quarter and first nine months of 2019 and 2018 primarily consist of severance costs and fees for professional services.

(b) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(c) During 2018, we incurred costs primarily related to the closure of our Clarence, NY facility.

(d) Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce costs and improve operational efficiencies. Expenses for the third quarter and first nine months of 2019 and 2018 primarily include severance costs and fees for professional services.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion. For 2019, Other Operating Expenses is expected to be approximately $10 million to $13 million.

- 39 -

### Interest Expense

Interest Expense for the three and nine months ended September 27, 2019 was $12.3 million and $39.8 million, respectively, compared to $54.5 million and $85.4 million for the three and nine months ended September 28, 2018. We paid down $36.3 million of debt during the third quarter of 2019 and $102.1 million during the first nine months of 2019 on our Term Loan Facilities. The weighted average interest rates paid on outstanding borrowings for the three and nine months ended September 27, 2019 was 4.96% and 5.08%, respectively, compared to 4.95% and 4.97%, for the comparable periods in 2018. The weighted average interest rates paid in 2019 reflect increases in LIBOR during 2018, partially offset by reductions to the applicable interest rate margin of our Term Loan A. Cash interest expense decreased $1.7 million and $4.3 million for the three and nine months ended September 27, 2019, when compared to the same periods in 2018, primarily due to the decrease in outstanding borrowings.

Debt related charges included in interest expense (i.e. debt issuance costs and discount amortization) for the three and nine months ended September 27, 2019 were $1.6 million and $5.3 million, respectively, compared to $42.1 million and $46.5 million for the three and nine months ended September 28, 2018. The decrease in debt related charges during the three and nine months periods of 2019 compared to the same periods in 2018 is primarily attributable to lower accelerated write-offs (losses from extinguishment of debt) of deferred fees and original issue discount related to prepayments of portions of our Term Loan B facility and Senior Notes during the respective periods and a “make-whole” premium of $31.3 million paid as a result of redeeming our Senior Notes in July 2018. We recognized losses from extinguishment of debt during the three and nine months ended September 27, 2019 of $0.3 million and $1.3 million, respectively, compared to $40.7 million and $42.1 million for the three and nine months ended September 28, 2018. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

As of September 27, 2019, approximately 20% of our principal amount of debt outstanding was subject to variable rates, in comparison to approximately 79% as of December 28, 2018. During the second and third quarters of 2019, we entered into interest rate swap agreements that we expect will further reduce our exposure to fluctuations in the LIBOR rate. These swap agreements convert $475 million of our outstanding debt to fixed rate indebtedness for the next six to nine months, as well as extended our $200 million interest rate swap for an additional three years.

### (Gain) Loss on Equity Investments, Net

During the three and nine months ended September 27, 2019, we recognized net gains of $1.0 million and net losses of $0.7 million, respectively, compared to net gains of $0.3 million and $5.5 million during the three and nine months ended September 28, 2018, respectively, on our equity investments. Gains and losses on equity investments are generally unpredictable in nature. During the second quarter of 2019, we recognized an impairment charge of $1.6 million related to an investment in one of our non-marketable equity securities. The residual amounts for 2019 and 2018 relate to our share of equity method investee gains/losses, including unrealized appreciation of the underlying interests of the investee. As of September 27, 2019 and December 28, 2018, we held $22.1 million and $22.8 million, respectively, of equity investments. See Note 14 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

### Other (Income) Loss, Net

Other (Income) Loss, Net for the three and nine months ended September 27, 2019 was income of $0.4 million and $0.9 million, respectively, compared to losses of $1.7 million and $0.3 million for the three and nine months ended September 28, 2018, respectively. Other (Income) Loss, Net is primarily comprised of income (loss) from the impact of foreign currency exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan pesos or Malaysian ringgits.

The impact of foreign currency exchange rates on transactions denominated in foreign currencies included in Other (Income) Loss, Net for the three and nine months ended September 27, 2019 were gains of $0.3 million and $0.4 million, respectively, compared to losses of $1.7 million and $0.8 million for the three and nine months ended September 28, 2018, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in foreign currency exchange rates could have a significant impact, positive or negative, on our financial results in the future.

- 40 -

### Provision for Income Taxes

We recognized income tax expense of $4.9 million (effective tax rate of 13.8%) for the third quarter of 2019 on $35.5 million of pre-tax income from continuing operations compared to income tax benefit of $6.2 million (effective tax rate of 42.6%) on $14.5 million of pre-tax loss from continuing operations for the same period of 2018. The income tax expense for the first nine months of 2019 was $15.3 million (effective tax rate of 16.0%) on income from continuing operations before taxes of $95.5 million compared to $8.0 million (effective tax rate of 22.2%) on $35.8 million of income from continuing operations before taxes for the same period of 2018.

Our effective tax rate for the third quarter and first nine months of 2019 differs from the third quarter and first nine months of 2018 due principally to the impact of the Global Intangible Low-Taxed Income (GILTI) tax, as well as the impact of our earnings realized in foreign jurisdictions with statutory rates that are different than the federal statutory rate. The GILTI provisions require the inclusion of our foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. As of the third quarter of 2018, we had net operating losses to offset substantially all of our forecasted U.S. taxable income and as such, were temporarily subject to the deduction limitation, which correspondingly imposes an incremental impact on U.S. income tax. We are not forecasting a limitation of the GILTI deduction in 2019.

We expect continued volatility in our effective tax rate due to several factors including: changes in the mix of pre-tax income from continuing operations and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place and continuously evaluate planning strategies aimed at reducing our effective tax rate over the long term. This includes strategies to realize deferred tax assets that would otherwise expire unutilized.

Our effective tax rate for 2019 differs from the U.S. federal statutory tax rate of 21% due principally to the net impact of the GILTI tax, the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, and the availability of tax credits.

Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

- 41 -

### Liquidity and Capital Resources

*(dollars in thousands)*

|  | September 27, 2019 | December 28, 2018 |
| --- | ---: | ---: |
| Cash and cash equivalents | $14,719 | $25,569 |
| Working capital | 264,133 | 251,680 |
| Current ratio | 2.40 | 2.53 |

Cash and cash equivalents at September 27, 2019 decreased by $10.9 million from December 28, 2018 as excess cash on hand was used to pay down our debt. Working capital increased by $12.5 million from December 28, 2018, primarily due to an increase in accounts receivable, inventories and prepaid and other current assets, partially offset by the reduced cash balance and increase in accounts payable.

At September 27, 2019, $5.4 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

### Summary of Cash Flow

*(in thousands)*

| Cash provided by (used in): | Nine Months Ended September 27, 2019 | September 28, 2018 |
| --- | ---: | ---: |
| Operating activities | $111,977 | $120,736 |
| Investing activities | (20,382) | 549,155 |
| Financing activities | (102,432) | (692,896) |
| Effect of foreign currency exchange rates on cash and cash equivalents | (13) | 1,790 |
| Net change in cash and cash equivalents | $(10,850) | $(21,215) |

The cash flow information presented includes cash flows related to the discontinued operations.

***Operating Activities –*** During the nine months ended September 27, 2019, we generated cash from operations of $112.0 million compared to $120.7 million for the nine months ended September 28, 2018. This decrease was primarily due to a $21.2 million decrease in cash flow provided by working capital, partially offset by a $12.5 million increase in cash net income (i.e. net income plus adjustments to reconcile net income to net cash provided by operating activities). The cash flow from working capital change during the period was primarily due to higher accounts receivable due to timing as well as the payment of customer rebates.

***Investing Activities –*** The $569.5 million decrease in net cash used in investing activities was primarily attributable to the lower net cash proceeds from the sale of the AS&O Product Line, partially offset by lower purchases of property, plant, and equipment, due to the sale of the AS&O Product Line. Investing activities for the nine months ended September 27, 2019 included $4.8 million of cash proceeds from Viant (received during the second quarter of 2019) resulting from the net working capital adjustment for the sale of the AS&O Product Line, compared to net cash proceeds from the sale of approximately $582 million (received during the third quarter of 2018).

Our current expectation is that capital purchases for 2019 will be in the range of $50 million to $55 million. We anticipate that cash on hand, cash flows from operations and available borrowing capacity under our Revolving Credit Facility will be sufficient to fund these capital expenditures.

***Financing Activities –*** Net cash used in financing activities for the nine months ended September 27, 2019, was $102.4 million compared to $692.9 million in the comparable 2018 period. Financing activities during the first nine months of 2019 included net payments of $102.1 million related to paying down our debt obligations compared to $670.1 million for the comparable 2018 period.

In connection with the completion of the sale of our AS&O Product Line, during the third quarter of 2018 we repaid $548 million of our debt, which included $360 million of our 9.125% Senior Notes, $114 million of our Term Loan B Facility and $74 million outstanding on our Revolving Credit Facility.

- 42 -

***Capital Structure –*** As of September 27, 2019, our capital structure consists of $828 million of debt, net of deferred fees and discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We have access to $193 million of borrowing capacity under our Revolving Credit Facility. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. Our debt service obligations, comprised of principal and interest payments for the remainder of 2019, are estimated to be approximately $20 million.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and potential borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.

***Credit Facilities*** - As of September 27, 2019, we had senior secured credit facilities (the “Senior Secured Credit Facilities”) that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), which had available borrowing capacity of $193.2 million as of September 27, 2019, (ii) a $277 million term loan A facility (the “TLA Facility”), and (iii) an $563 million term loan B facility (the “TLB Facility”). The Revolving Credit Facility will mature on October 27, 2020, the TLA Facility will mature on October 27, 2021 and the TLB Facility will mature on October 27, 2022.

The Revolving Credit Facility and TLA Facility contain financial covenants requiring (A) a maximum total net leverage ratio of 4.75:1.0, subject to quarterly step downs of 25 basis points beginning in the fourth quarter of 2019 and ending in the second quarter of 2020, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 3.0:1.0. The TLB Facility does not contain any financial maintenance covenants. As of September 27, 2019, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 2.7 to 1.0. For the twelve month period ended September 27, 2019, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 6.5 to 1.0.

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of September 27, 2019, we were in full compliance with the financial covenants described above. As of September 27, 2019, our adjusted EBITDA would have to decline by approximately $129 million, or approximately 42%, in order for us to not be in compliance with our financial covenants. The Revolving Credit Facility is supported by a consortium of fourteen lenders with no lender controlling more than 27% of the facility.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended September 27, 2019 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 28, 2018.

- 43 -

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 28, 2018.

### Use of Non-GAAP Financial Information

We prepare our condensed consolidated financial statements in accordance with GAAP. Additionally, we report and discuss in this management's discussion and analysis, our earnings releases and investor presentations adjusted pre-tax income, adjusted income, adjusted diluted EPS, EBITDA and adjusted EBITDA, all from continuing operations.

Adjusted pre-tax income, adjusted income and adjusted diluted EPS from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related charges and expenses, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain litigation expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain/loss on equity investments, (ix) extinguishment of debt charges, (x) the net impact of long-term supply agreements (“LSAs”) entered into as of the closing of the divestiture of the AS&O Product Line, (xi) the income tax (benefit) related to these adjustments (not for adjusted pre-tax income) and (xii) certain tax items that are outside the normal provision for the period (not for adjusted pre-tax income). Adjusted diluted EPS is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding.

EBITDA from continuing operations is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure. Adjusted EBITDA from continuing operations consists of EBITDA from continuing operations plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (xi) and (xii).

We believe that the presentation of adjusted income, adjusted diluted EPS, EBITDA, and adjusted EBITDA, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations, including compliance with our bank covenant calculations.

- 44 -

### Income from Continuing Operations and Diluted EPS Reconciliations

A reconciliation of GAAP income (loss) from continuing operations and diluted EPS from continuing operations to adjusted amounts is as follows (in thousands, except per share amounts):

|  | Three Months Ended September 27, 2019 Pre-Tax Net of Tax Per Diluted Share | September 28, 2018 Pre-Tax Net of Tax Per Diluted Share |
| --- | ---: | ---: |
| Income (loss) from continuing operations (GAAP) | $35,499 $30,586 $0.92 | $(14,460) $(8,303) $(0.26) |
| Adjustments: |  |  |
| Amortization of intangibles(a) | 9,782 7,750 0.23 | 9,896 7,830 0.24 |
| Certain legal expenses (SG&A)(a)(b) | 99 78 — | 749 591 0.02 |
| Strategic reorganization and alignment (OOE)(a)(c) | 962 740 0.02 | 2,643 2,085 0.06 |
| Manufacturing alignment to support growth (OOE)(a)(d) | 515 366 0.01 | 877 657 0.02 |
| Consolidation and optimization expenses (OOE)(a)(e) | — — — | 137 108 — |
| Asset dispositions, severance and other (OOE)(a)(f) | 764 604 0.02 | 482 412 0.01 |
| Gain on equity investments, net(a) | (986) (779) (0.02) | (291) (230) (0.01) |
| Loss on extinguishment of debt(a)(g) | 291 230 0.01 | 40,654 32,117 0.98 |
| Tax adjustments(h) | — — — | — (417) (0.01) |
| Adjusted income from continuing operations (Non-GAAP) | $46,926 $39,575 $1.20 | $40,687 $34,850 $1.06 |
| Diluted weighted average shares for adjusted EPS(j) | 33,068 | 32,899 |
|  | **Nine Months Ended** |  |
|  | **September 27, 2019** | **September 28, 2018** |
|  | **Pre-Tax** **Net of Tax** **Per Diluted Share** | **Pre-Tax** **Net of Tax** **Per Diluted Share** |
| Income from continuing operations (GAAP) | $95,463 $80,174 $2.43 | $35,793 $27,837 $0.86 |
| Adjustments: |  |  |
| Amortization of intangibles(a) | 29,467 23,324 0.71 | 31,068 24,523 0.75 |
| Certain legal expenses (SG&A)(a)(b) | 2,175 1,718 0.05 | 1,546 1,221 0.04 |
| Strategic reorganization and alignment (OOE)(a)(c) | 4,352 3,377 0.10 | 8,424 6,662 0.20 |
| Manufacturing alignment to support growth (OOE)(a)(d) | 1,661 1,173 0.04 | 2,493 1,841 0.06 |
| Consolidation and optimization expenses (OOE)(a)(e) | — — — | 698 553 0.02 |
| Asset dispositions, severance and other (OOE)(a)(f) | 2,226 1,756 0.05 | 1,000 776 0.02 |
| (Gain) loss equity investments, net(a) | 666 526 0.02 | (5,545) (4,381) (0.13) |
| Loss on extinguishment of debt(a)(g) | 1,265 999 0.03 | 42,128 33,281 1.02 |
| LSA adjustments(a)(i) | — — — | (6,119) (4,834) (0.15) |
| Tax adjustments(h) | — — — | — 2,534 0.08 |
| Adjusted income from continuing operations (Non-GAAP) | $137,275 $113,047 $3.42 | $111,486 $90,013 $2.75 |
| Diluted weighted average shares for adjusted EPS(j) | 33,019 | 32,681 |

- 45 -

(a) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates in Mexico, Netherlands, Uruguay, Ireland and Switzerland, as adjusted for the existence of net operating losses (“NOLs”). Amortization of intangibles and other operating expense for 2018 were adjusted to reflect the estimated impact relating to our disallowed deduction of the GILTI tax, as described in footnote (h) below. Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) In 2013, we filed suit against AVX Corporation alleging it was infringing our intellectual property. Given the complexity and significant costs incurred pursuing this litigation, we are excluding these litigation expenses from adjusted amounts. This matter proceeded to trial during the first quarter of 2016 and again in the third quarter of 2017 that resulted in a jury awarding damages in the amount of $37.5 million. In March 2018, the court vacated that damage award and ordered a new trial on damages. In the January 2019 retrial on damages, the jury awarded damages in the amount of $22.2 million. To date, no gains have been recognized in connection with this litigation. The third quarter and nine months ended September 27, 2019 also includes costs associated with a legal matter to which we are a non-party witness.

(c) Amounts include expenses related to implementing our strategy that is designed to better align our resources in order to invest to grow, protect, preserve and to enhance the profitability of our portfolio of products, including focusing our investment in RD&E and manufacturing, improving our business processes and redirecting investments away from projects where the market does not justify the investment. During 2019 and 2018, we incurred charges related to this strategy, which primarily consisted of severance costs and fees for professional services.

(d) Includes expenses related to several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(e) During 2018, we incurred costs primarily related to the closure of our Clarence, NY facility.

(f) Amounts include expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce costs and improve operational efficiencies.

(g) Represents debt extinguishment charges in connection with pre-payments made on our Term Loan B Facility, which are included in interest expense.

(h) The tax adjustment for 2018 represents the estimated impact relating to our disallowed deduction of the GILTI tax, as mandated by the Tax Reform Act. This disallowed deduction of the GILTI tax (approximately 50% of the total GILTI tax) is due to the Company making use of its U.S. NOLs during 2018. This adjustment makes our adjusted diluted EPS from continuing operations more comparable with other global companies that are not subject to this disallowed GILTI tax deduction and more comparable to the Company’s results following the full utilization of its U.S. NOLs.

(i) Reflects the net impact of the LSAs entered into as of the closing of the divestiture of the AS&O Product Line. These LSAs govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.

(j) The diluted weighted average shares for adjusted EPS for the three and nine months ended September 28, 2018 includes potentially dilutive shares not included in the computation of diluted weighted average common shares for GAAP diluted EPS purposes because their effect would have been anti-dilutive.

- 46 -

### EBITDA and Adjusted EBITDA Reconciliation

A reconciliation of GAAP income (loss) from continuing operations to EBITDA from continuing operations and adjusted EBITDA from continuing operations is as follows (dollars in thousands):

|  | Three Months Ended September 27, 2019 | September 28, 2018 | Nine Months Ended September 27, 2019 | September 28, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Income (loss) from continuing operations (GAAP) | $30,586 | $(8,303) | $80,174 | $27,837 |
| Interest expense | 12,337 | 54,526 | 39,779 | 85,355 |
| Provision for (benefit from) income taxes | 4,913 | (6,157) | 15,289 | 7,956 |
| Depreciation | 9,080 | 9,960 | 27,930 | 29,929 |
| Amortization | 9,782 | 9,896 | 29,467 | 31,068 |
| EBITDA from continuing operations (Non-GAAP) | 66,698 | 59,922 | 192,639 | 182,145 |
| Certain legal expenses | 99 | 749 | 2,175 | 1,546 |
| Stock-based compensation (excluding OOE) | 1,392 | 2,087 | 6,778 | 7,265 |
| Strategic reorganization and alignment | 962 | 2,643 | 4,352 | 8,424 |
| Manufacturing alignment to support growth | 515 | 877 | 1,661 | 2,493 |
| Consolidation and optimization expenses | — | 137 | — | 698 |
| Asset dispositions, severance and other | 764 | 482 | 2,226 | 1,000 |
| (Gain) loss on equity investments, net | (986) | (291) | 666 | (5,545) |
| LSA adjustments | — | — | $— | $(6,119) |
| Adjusted EBITDA from continuing operations (Non-GAAP) | $69,444 | $66,606 | $210,497 | $191,907 |

- 47 -

## Market risk

As filed, 541 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 28, 2018. There have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,421 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of September 27, 2019. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of September 27, 2019, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 48 -

## Risk factors

As filed, 171 characters.

There have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 28, 2018.

Filed Oct 31, 2019.
Source: SEC EDGAR, the filing index for accession 0001114483-19-000025. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
